Efficacy and Safety of Arotinolol Hydrochloride on Morning Blood Pressure and Heart Rate
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 198 participants.
Also called NCT02612298
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 198 participants
- Registry
-
NCT02612298
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT02612298. Randomized; no masking; primary purpose treatment. Start 2015-08 (actual); primary completion 2018-09-13 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Arotinolol Hydrochloride on Morning Blood Pressure and Heart Rate
- Acronym
- ESAHOM
- Condition
- Essential Hypertension
- Intervention (Drug)
- Arotinolol Hydrochloride
- Intervention (Drug)
- Metoprolol succinate sustained-release tablet
- Lead sponsor
- Marubeni Pharmaceuticals (Suzhou) Co., Ltd.
Record details
- Record id
cardio:ct-nct02612298- Content hash
e8c9d5a5dd9969016dcc100ebaea78ef217ac674f319ee65c2395ef15b9dec8d